Study results published in Lancet Infectious Diseases show Vaxart’s tablet vaccine elicited protective responses against a specific influenza protein (hemagglutinin) in more than 90% percent of subjects after a single dose. The vaccine also generated robust mucosal responses, suggesting vaccines based on the Vaxart platform could offer advantages over injectable vaccines in their ability to protect against mucosal pathogens in the gut.
In a Phase 2 influenza challenge study, Vaxart’s tablet vaccine demonstrated protection against illness comparable to that of the best-selling injectable influenza vaccine. In this study, the vaccine generated mucosal immune responses that were highly correlated with protection, a result not seen with the injectable vaccine.
Two Phase 1 norovirus clinical studies demonstrated Vaxart’s tablet vaccine generated mucosal immune responses that were rapid and homed to the small intestine, the site of norovirus infection. Presence of norovirus-specific fecal antibodies at day 180 post-immunization demonstrated persistence of the immune response.